Compare Abeona Therapeutics Inc (ABEO) vs ARK Innovation ETF (ARKK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ARK Innovation ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while ARK Innovation ETF trades at $79.76. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | ARKK | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $92.50 |
52-Week Low | $4.17 | $63.52 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ARK Innovation ETF (ARKK) trades at $83.61, up 2.9% with a bullish technical outlook from moving averages. The ETF faces mixed sentiment with concerns about its 0.75% expense ratio and 37.88% five-year loss, though recent inflows and AI-focused portfolio shifts show renewed investor interest. Tesla's 10% weighting remains a key driver, while technical indicators show overbought short-term RSI but strong trend momentum.
Outlook hinges on ARKK's concentrated bets in disruptive innovation stocks amid AI momentum, but high fees and volatility pose risks. The ETF's performance remains tied to Tesla and Cathie Wood's stock-picking, with current technical strength suggesting near-term upside if support at $82 holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →
